Forxiga is indicated for monotherapy and combination therapy use to improve glycemic control with the additional benefits of weight loss and blood pressure reduction.
18 July 2019 Comment
17 June 2019 Comment
Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled
Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in cardiovascular disease (CVD) risk reduction, there could be future competition...
23 April 2019 pressreleases
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
27 March 2019 Comment
Abbott’s MagLev pump technology is thought to be responsible for the reduction of many severe complications of end-stage heart failure treatment.
25 March 2019 Comment
Minimally invasive interventions for treating peripheral artery disease (PAD) are growing as they continue to demonstrate better patient outcomes compared to pharmaceutical treatment and open surgery.
14 March 2019 News
Researchers from the Stanford University School of Medicine have discovered that AMPK activators, which include metformin for type 2 diabetes, could mitigate the cardiac side effects of chemotherapy drug trastuzumab.
13 March 2019 Comment
Only two pipeline agents in the cardiovascular space are expected to reach blockbuster status (with sales over $1 billion) by 2024.
4 March 2019 News
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for blood pressure and heart...
28 February 2019 News
Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases.